Literature DB >> 10770945

The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement.

D M Hoover1, L S Mizoue, T M Handel, J Lubkowski.   

Abstract

Fractalkine, or neurotactin, is a chemokine that is present in endothelial cells from several tissues, including brain, liver, and kidney. It is the only member of the CX(3)C class of chemokines. Fractalkine contains a chemokine domain (CDF) attached to a membrane-spanning domain via a mucin-like stalk. However, fractalkine can also be proteolytically cleaved from its membrane-spanning domain to release a freely diffusible form. Fractalkine attracts and immobilizes leukocytes by binding to its receptor, CX(3)CR1. The x-ray crystal structure of CDF has been solved and refined to 2.0 A resolution. The CDF monomers form a dimer through an intermolecular beta-sheet. This interaction is somewhat similar to that seen in other dimeric CC chemokine crystal structures. However, the displacement of the first disulfide in CDF causes the dimer to assume a more compact quaternary structure relative to CC chemokines, which is unique to CX(3)C chemokines. Although fractalkine can bind to heparin in vitro, as shown by comparison of electrostatic surface plots with other chemokines and by heparin chromatography, the role of this property in vivo is not well understood.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770945     DOI: 10.1074/jbc.M002584200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Microglia in Health and Disease.

Authors:  Richard M Ransohoff; Joseph El Khoury
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-09       Impact factor: 10.005

2.  Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain.

Authors:  Patricia Hermand; Frédéric Pincet; Stéphanie Carvalho; Hervé Ansanay; Eric Trinquet; Mehdi Daoudi; Christophe Combadière; Philippe Deterre
Journal:  J Biol Chem       Date:  2008-08-25       Impact factor: 5.157

Review 3.  Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function.

Authors:  C L Salanga; T M Handel
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

Review 4.  Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.

Authors:  R Cotter; C Williams; L Ryan; David Erichsen; A Lopez; H Peng; J Zheng
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions.

Authors:  E Sonay Kuloğlu; Darrell R McCaslin; John L Markley; Brian F Volkman
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

Review 6.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

7.  Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data.

Authors:  Xu Wang; Caroline Watson; Joshua S Sharp; Tracy M Handel; James H Prestegard
Journal:  Structure       Date:  2011-08-10       Impact factor: 5.006

Review 8.  Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.

Authors:  Irina Kufareva; Catherina L Salanga; Tracy M Handel
Journal:  Immunol Cell Biol       Date:  2015-02-24       Impact factor: 5.126

Review 9.  Chemokines and their receptors: insights from molecular modeling and crystallography.

Authors:  Irina Kufareva
Journal:  Curr Opin Pharmacol       Date:  2016-07-25       Impact factor: 5.547

Review 10.  Chemokine oligomerization in cell signaling and migration.

Authors:  Xu Wang; Joshua S Sharp; Tracy M Handel; James H Prestegard
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.